Eylea Market Thrives On Addressing The Rise In Ocular Diseases: Transformative Forces Shaping the Eylea Market Landscape in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Eylea Industry Market Size Be by 2025?
There has been a robust expansion in the eylea market size over the past few years. The market, which will rise from $9.94 billion in 2024, is projected to hit $10.51 billion in 2025, representing a compound annual growth rate (CAGR) of 5.7%. This significant growth during the historic period can be linked to an increasing incidence of diabetic macular edema (DME), assured clinical effectiveness and safety, competition with alternative anti-VEGF therapies, endorsements for diverse retinal conditions, and a trend towards intravitreal injections.

What's the Long-Term Growth Forecast for the Eylea Market Size Through 2029?
There is an anticipation of robust expansion in the eylea market in the coming years. The market is predicted to scale to "$13.64 billion by 2029, escalating at a compound annual growth rate (CAGR) of 6.7%. Factors inducing growth during the projected timeframe include the upsurge in therapeutic indications, the advent of biosimilar competition, an increase in diagnosis and awareness, empirical evidence and studies post-market, and patients favoring less frequent injections. The forthcoming period is likely to witness trends such as improvements in imaging technologies, the rise of telemedicine and remote observation, patient support initiatives, upgrades in drug delivery mechanisms, advancements in retinal imaging technologies, and clinical trials aiming at new indications.

View the full report here:
https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

What Are the Key Growth Drivers Fueling the Eylea Market Expansion?
The surge in ocular diseases, a type of eye disorder that impedes the eye's proper functioning while impairing vision and eye clarity, is set to drive the Eylea market forward. These diseases generally don't show any indications until they've progressed significantly. Eylea is an effective treatment for ocular diseases, including wet age-related macular degeneration (AMD) and glaucoma, conditions that damage the retina or macula, affecting vision. Eylea acts by blocking the protein that triggers the formation of weaker new blood vessels and reduces the swelling in the retina caused by blocked blood vessels. For example, the BrightFocus Foundation, a US non-profit organization focused on promoting research and support for macular degeneration and glaucoma, stated in October 2022 that there were 80 million glaucoma sufferers worldwide, with numbers expected to rise to over 111 million by 2040. Consequently, the rising occurrence of ocular diseases propels the Eylea market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

What Are the Key Trends Driving Eylea Market Growth?
In the eylea market, one of the emerging trends is the emphasis on research and development. Major players in the industry are focusing on creating innovative technical solutions for eylea. For example, Regeneron Pharmaceuticals, Inc., a biotechnology company from the US that focuses on the development of drugs for severe diseases, got approval from the US FDA in August 2023 for Eylea HD (aflibercept) injection 8 mg. This is intended for patients suffering from wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The injection schedule includes an initial period of every four weeks during the first quarter across all indications. Then, the schedule modifies to intervals of every eight to 16 weeks for wAMD and DME, and every eight to 12 weeks for diabetic retinopathy.

How Is the Eylea Market Segmented?
The eylea market covered in this report is segmented -

1) By Product: Prefilled Syringe Package, Vial Package
2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders
3) By Application: Hospitals, Retail Pharmacy, Other Applications

Subsegments:
1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes
2) By Vial Package: Single-Dose Vials, Multi-Dose Vials

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9155&type=smp

Which Companies Are Leading the Charge in Eylea Market Innovation?
Major companies operating in the eylea market include Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., GlaxoSmithKline plc, Biogen Inc., Alcon Inc., Johnson & Johnson, Eli Lilly and Company, Genentech Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Samsung Bioepis Co. Ltd., Lupin Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals LLC, Apotex Inc.

Which Regions Are Leading the Global Eylea Market in Revenue?
North America was the largest region in the eylea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9155

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.